[1] McKee FW,Schloerb PR.Protein metabolism and exchange as influenced by constriction of the vena cava;experimental ascites as internal plasmapheresis;sodium chloride and protein intake predominant factors[J].J Exp Med,1948,87(6):457-471. [2] Padmanabhan A,Connelly-Smith L,Aqui N,et al.Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis:the eighth special issue[J].J Clin Apher,2019,34(3):171-354. [3] Szczepiorkowski ZM,Bandarenko N,Kim HC,et al.Guidelines on the use of therapeutic apheresis in clinical practice-Evidence-based approach from the apheresis applications committee of the American society for apheresis[J].J Clin Apheresis,2007,22(3):106-175. [4] 王学文,张桂如.血浆置换术的进展及临床应用价值[J].医师进修杂志,1984(11):18-20. [5] 陈立,李忠俊.如何构建我国治疗性血浆置换术的教学体系[J].临床输血与检验,2018,20(3):228-231. [6] Orlin JB,Berkman EM.Partial plasma exchange using albumin replacement:removal and recovery of normal plasma constituents[J].Blood,1980,56(6):1055-1059. [7] R. W.Basic principles of therapeutic blood exchange. In: McLeod BC, Price TH, Weinstein R, eds. Apheresis: Principles and practice. 2nd ed. [M]. Bethesda, MD: AABB Press2003: 295-320. [8] Jones HGBN.Management of the therapeutic apheresis patient. In: McLeod BC, Price TH, Weinstein R, eds. Apheresis: Principles and practice. 2nd ed. [M]. Bethesda, MD: AABB Press2003: 253-282. [9] Bauer E,Derfler K,Joukhadar C,et al.Citrate kinetics in patients receiving long-term hemodialysis therapy[J].Am J Kidney Dis,2005,46(5):903-907. [10] Kramer L,Bauer E,Joukhadar C,et al.Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients[J].Crit Care Med,2003,31(10):2450-2455. [11] Weinstein R.Hypocalcemic toxicity and atypical reactions in therapeutic plasma exchange[J].J Clin Apher,2001,16(4):210-211. [12] Bolan CD,Greer SE,Cecco SA,et al.Comprehensive analysis of citrate effects during plateletpheresis in normal donors[J].Transfusion,2001,41(9):1165-1171. [13] Jones J S,Dougherty J.Current status of plasmapheresis in toxicology[J].Ann Emerg Med,1986,15(4):474-482. [14] Sketris IS PW, Jones JV.Effect of plasma exchange on drug removal. In: Valbonesi M, Pineda AA, Biggs JC, eds. [M]. Therapeutic Hemapheresis Milan, Italy: Wichtig Editore1986: 15-20. [15] Chan GL,Hodge EE.Effect of plasmapheresis on cyclosporine pharmacokinetics[J].DICP,1991,25(2):211. [16] Przepiorka D,Suzuki J,Ippoliti C,et al.Blood tacrolimus concentration unchanged by plasmapheresis[J].Am J Hosp Pharm,1994,51(13):1708. [17] Cheng CW,Hendrickson JE,Tormey CA,et al.Therapeutic plasma exchange and its impact on drug LevelsAn ACLPS critical review[J].Am J Clin Pathol,2017,148(3):190-198. [18] Puisset F,White-Koning M,Kamar N,et al.Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease[J].Br J Clin Pharmacol,2013,76(5):734-740. [19] Kim SH,Kim W,Huh SY,et al.Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels[J].J Clin Neurol,2013,9(1):36-42. [20] 庄远,徐全刚,魏世辉.血浆置换治疗急性期视神经炎[J].眼科,2017,26(1):6-9. [21] Fazeli B,Rafatpanah H,Ravari H,et al.Sera of patients with thromboangiitis obliterans activated cultured human umbilical vein endothelial cells (HUVECs) and changed their adhesive properties[J].Int J Rheum Dis,2014,17(1):106-112. [22] Koyama R,Kato M,Yamashita S,et al.Hypoglycemia and hyperglycemia due to insulin antibodies against therapeutic human insulin:treatment with double filtration plasmapheresis and prednisolone[J].Am J Med Sci,2005,329(5):259-264. [23] Loïc Guillevin.Plasma exchanges. A still effective treatment[J]. Presse Med,2019,48(11 Pt 2): 317-318 |